VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SNN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
SNNSmith & Nephew plc
$30.48$12.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

SNN logoSmith & Nephew plc(SNN)Earnings, Financials & Key Ratios

SNN•NYSE
$30.48
21.2× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryOrthopedics, spine, and sports medicine
AboutSmith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.Show more
  • Revenue$6.18B+6.3%
  • EBITDA$1.58B+27.7%
  • Net Income$626M+52.1%
  • EPS (Diluted)1.44+53.2%
  • Gross Margin68.01%-2.3%
  • EBITDA Margin25.57%+20.1%
  • Operating Margin16.27%+43.9%
  • Net Margin10.14%+43.0%
  • ROE11.87%+51.0%

SNN Price & Volume

Smith & Nephew plc (SNN) stock price & volume — 10-year historical chart

Loading chart...

Operational Efficiency Gains Support Improving Cash Flow

Investment Thesis • Updated 2025Q4

VerdictNeutral
Growth:Expanding
Profitability:Moderate
Financial:Healthy
Cash Flow:Improving
Primary Risk:Margin compression from competition

Key Thesis Takeaways

  • Smith & Nephew is navigating a transition phase where revenue growth of 7.0% in 2025Q4 suggests a successful recovery in elective procedure volumes.
  • While the firm's 12-Point Plan aims to drive operational efficiency, investors should monitor the contraction of gross margins to 65.6% and the persistent $3.1 billion goodwill balance for potential impairment risks.
  • The company's shift toward returning capital, evidenced by $503.2 million in share repurchases, reflects a maturing cash flow profile that warrants cautious optimism regarding long-term shareholder value creation.

Verdict Logic

while the firm demonstrates improved liquidity with a current ratio of 2.57, the forward P/E of 13.59 and margin volatility suggest that investors should wait for more consistent operational leverage before increasing exposure.

SNN Growth Metrics

Smith & Nephew plc (SNN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years2.92%
5 Years6.26%
3 Years5.81%
TTM11.38%

Profit CAGR

10 Years4.33%
5 Years6.94%
3 Years41.1%
TTM113.67%

EPS CAGR

10 Years4.58%
5 Years7.14%
3 Years42.28%
TTM116.22%

Return on Capital

10 Years9.14%
5 Years6.98%
3 Years8.21%
Last Year11.37%

SNN Recent Earnings

Smith & Nephew plc (SNN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Mar 3, 2026
Metric
Actual
Est
EPS
$1.18+1.7%
$1.16
Rev
$3.2B+15.5%
$2.8B
Q2 2026
Mar 2, 2026
Metric
Actual
Est
EPS
$1.18+1.7%
$1.16
Rev
$3.2B+15.5%
$2.8B
Q3 2025
Aug 5, 2025
Metric
Actual
Est
EPS
$0.67-21.7%
$0.86
Rev
$3.0B+98.0%
$1.5B
Q1 2025
Feb 25, 2025
Metric
Actual
Est
EPS
$0.23-75.5%
$0.92
Rev
$3.0B+96.0%
$1.5B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMar 3, 2026
$1.18vs $1.16+1.7%
$3.2Bvs $2.8B+15.5%
Q2 2026Mar 2, 2026
$1.18vs $1.16+1.7%
$3.2Bvs $2.8B+15.5%
Q3 2025Aug 5, 2025
$0.67vs $0.86-21.7%
$3.0Bvs $1.5B+98.0%
Q1 2025Feb 25, 2025
$0.23vs $0.92-75.5%
$3.0Bvs $1.5B+96.0%
Based on last 12 quarters of dataView full earnings history →

Latest SNN News

Recent stock market news and headlines for Smith & Nephew plc (SNN)

Seeking Alpha·Jun 25, 2026
Smith & Nephew: Ongoing Business Progress And A More Attractive Price

Smith & Nephew continues to demonstrate solid business recovery, with robust revenue, profit, and free cash flow growth across all divisions. SNN's 2026 outlook targets 6% underlying revenue growth, 8% organic trading profit growth, and $800 million in free cash flow, with a new $500 million share buyback announced. Completion of the 12-point plan delivered mixed results: revenue growth targets were met, but trading margin fell short, prompting a new 'RISE' strategy with 2028 financial targets.

Peers Comparison

Key metrics vs top competitors for Smith & Nephew plc (SNN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SNN logoSNNSmith & Nephew plcCurrent
$30.48$12.91B21.176.34%10.14%11.87%2.49%
ZBH logoZBHZimmer Biomet Holdings, Inc.
$89.41$17.51B25.197.2%9.05%5.77%—
SYK logoSYKStryker Corporation
$313.38$120.14B37.3111.16%13.21%15.1%—
BSX logoBSXBoston Scientific Corporation
$45.30$67.33B23.3519.87%17.23%14.67%—
HOLX logoHOLXHologic, Inc.
$76.01$16.97B30.531.74%13.18%11.01%—
CNMD logoCNMDCONMED Corporation
$34.24$1.06B22.685.16%4%5.4%—

Compare SNN vs Peers

Smith & Nephew plc (SNN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ZBH

Most directly comparable listed peer for SNN.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare SNN against a more recognizable public peer.

Peer Set

Compare Top 5

vs ZBH, SYK, BSX, HOLX

Get notified when SNN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SNN Frequently Asked Questions

Smith & Nephew plc (SNN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Smith & Nephew plc's revenue?

Smith & Nephew plc (SNN) reported $11.99B in revenue for fiscal year 2025. This represents a 555% increase from $1.83B in 1996.

How fast is Smith & Nephew plc growing?

Smith & Nephew plc (SNN) grew revenue by 6.3% over the past year. This is steady growth.

Is SNN profitable?

Yes, Smith & Nephew plc (SNN) is profitable, generating $1.04B in net income for fiscal year 2025 (10.1% net margin).

Dividend & Returns
Does SNN pay dividends?

Yes, Smith & Nephew plc (SNN) pays a dividend with a yield of 2.49%. This makes it attractive for income-focused investors.

What is SNN's return on equity?

Smith & Nephew plc (SNN) has a return on equity (ROE) of 11.9%. This is reasonable for most industries.

What is Smith & Nephew plc's free cash flow?

Smith & Nephew plc (SNN) generated $1.46B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in SNN back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →